Evidence map›Paper›PMID 25706755›Full record

ArticlePloS one2015

Nanocytological field carcinogenesis detection to mitigate overdiagnosis of prostate cancer: a proof of concept study.

Hemant K Roy, Charles B Brendler, Hariharan Subramanian, Di Zhang, Charles Maneval, John Chandler, Leah Bowen, Karen L Kaul, Brian T Helfand, Chi-Hsiung Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Tissue spatial correlation as cancer marker.Journal of biomedical optics · 2019
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Hemant K RoyDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts, United States of America.
Charles B BrendlerDepartment of Surgery, NorthShore University HealthSystem, Evanston, Illinois, United States of America.
Hariharan SubramanianBiomedical Engineering Department, Northwestern University, Evanston, Illinois, United States of America.
Di ZhangBiomedical Engineering Department, Northwestern University, Evanston, Illinois, United States of America.
Charles ManevalBiomedical Engineering Department, Northwestern University, Evanston, Illinois, United States of America.
John ChandlerBiomedical Engineering Department, Northwestern University, Evanston, Illinois, United States of America.
Leah BowenBiomedical Engineering Department, Northwestern University, Evanston, Illinois, United States of America.
Karen L KaulDepartment of Pathology, NorthShore University HealthSystem, Evanston, Illinois, United States of America.
Brian T HelfandDepartment of Surgery, NorthShore University HealthSystem, Evanston, Illinois, United States of America.
Chi-Hsiung WangDepartment of Surgery, NorthShore University HealthSystem, Evanston, Illinois, United States of America.
Margo QuinnDepartment of Surgery, NorthShore University HealthSystem, Evanston, Illinois, United States of America.
Jacqueline PetkewiczDepartment of Surgery, NorthShore University HealthSystem, Evanston, Illinois, United States of America.
Michael PaterakosDepartment of Pathology, NorthShore University HealthSystem, Evanston, Illinois, United States of America.
Vadim BackmanBiomedical Engineering Department, Northwestern University, Evanston, Illinois, United States of America.
NorthShore University HealthSystem · USNorthwestern University · USUniversity Medical Center · US

Funding

Novel Biophotonics Methodology for Colon Cancer ScreeningR01CA128641 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM · 2008 to 2012
$7.3M
Spectral Markers for Early Detection of Colon NeoplasiaU01CA111257 · NCI · NORTHSHORE UNIV HEALTHSYSTEM RES INST · PI BACKMAN, VADIM, ROY, HEMANT K. · 2004 to 2015
$6.0M
Nanoscale/Molecular analysis of Fecal Colonocytes for Colorectal Cancer ScreeningR01CA165309 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, ROY, HEMANT K. · 2012 to 2016
$2.8M
Transforming Colorectal Cancer Screening through Multimodal Spectral MarkersR01CA156186 · NCI · ENDEAVOR HEALTH CLINICAL OPERATIONS · PI BACKMAN, VADIM, ROY, HEMANT K. · 2011 to 2015
$2.8M
Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer ScreeningR01CA155284 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, ROY, HEMANT K. · 2011 to 2014
$2.3M
Nanocytological Fecal Assessment to Personalize Colonoscopic SurveillanceR42CA168055 · NCI · NANOCYTOMICS, LLC · PI ROY, HEMANT K. · 2012 to 2014
$1.8M
NCI NIH HHS R01 CA128641NCI NIH HHS R01CA128641NCI NIH HHS R01 CA155284NCI NIH HHS R01CA155284NCI NIH HHS R01 CA156186NCI NIH HHS R01CA156186NCI NIH HHS R01 CA165309NCI NIH HHS R01CA165309NCI NIH HHS R42 CA168055NCI NIH HHS R42CA168055NCI NIH HHS U01 CA111257NCI NIH HHS U01CA111257
6 · The paper itself

Abstract

purposeTo determine whether nano-architectural interrogation of prostate field carcinogenesis can be used to predict prognosis in patients with early stage (Gleason 6) prostate cancer (PCa), which is mostly indolent but frequently unnecessarily treated. MATERIALS AND

methodsWe previously developed partial wave spectroscopic microscopy (PWS) that enables quantification of the nanoscale intracellular architecture (20-200 nm length scale) with remarkable accuracy. We adapted this technique to assess prostate needle core biopsies in a case control study from men with Gleason 6 disease who either progressed (n = 20) or remained indolent (n = 18) over a ~3 year follow up. We measured the parameter disorder strength (Ld) characterizing the spatial heterogeneity of the nanoscale cellular structure and nuclear morphology from the microscopically normal mucosa ~150 histologically normal epithelial cells.

resultsThere was a profound increase in nano-architectural disorder between progressors and non-progressors. Indeed, the Ld from future progressors was dramatically increased when compared to future non-progressors (1±0.065 versus 1.30±0.0614, respectively p = 0.002). The area under the receiver operator characteristic curve (AUC) was 0.79, yielding a sensitivity of 88% and specificity of 72% for discriminating between progressors and non-progressors. This was not confounded by demographic factors (age, smoking status, race, obesity), thus supporting the robustness of the approach.

conclusionsWe demonstrate, for the first time, that nano-architectural alterations occur in prostate cancer field carcinogenesis and can be exploited to predict prognosis of early stage PCa. This approach has promise in addressing the clinically vexing dilemma of management of Gleason 6 PCa and may provide a paradigm for dealing with the larger issue of cancer overdiagnosis.

Indexed as

AgedCarcinogenesisCase-Control StudiesEarly Detection of CancerHumansMaleMedical OveruseMiddle AgedNeoplasm GradingPrognosisProstateProstatic Neoplasms

Identifiers

PMID25706755
PMCPMC4338151
OpenAlexW2081696992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.